TNFSF14 Protein (AA 72-239, N-Term)

Catalog No. ABIN2666556

Recombinant TNFSF14 protein expressed in CHO Cells.

Quick Overview for TNFSF14 Protein (AA 72-239, N-Term) (ABIN2666556)

Target: TNFSF14 (Tumor Necrosis Factor (Ligand) Superfamily, Member 14 (TNFSF14))

Protein Type: Recombinant

Biological Activity: Active

Origin: Mouse

Source: CHO Cells

Application: Flow Cytometry (FACS)

Purity: > 95 % , as determined by Coomassie stained SDS-PAGE.

Product Details

Protein Characteristics: AA 72-239, N-Term

Sterility: 0.22 μm filtered

Endotoxin Level:

Less than 0.01 ng per μg cytokine as determined by the LAL method.

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

Biological activity: ED50 = 1.0 - 5.0 μg/mL, as determined by cytotoxicity effect of HTâ€'29 human colon adenocarcinoma cells in the presence of human IFN-γ.

Restrictions: For Research Use only

Handling

Format: Liquid

Reconstitution: For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20 °C to -70 °C. Stock solutions can also be prepared at 50 - 100 μg/mL in sterile buffer (PBS, HPBS, DPBS, or EBSS) containing carrier protein such as 0.2 - 1 % BSA or HSA and stored in working aliquots at -20 °C to -70 °C.

Buffer: 0.22 μm filtered protein solution is in PBS, pH 7.2.

Handling Advice: Avoid repeated freeze/thaw cycles.

Storage: -20 °C

Storage Comment: Unopened vial can be stored between 2°C and 8°C for one month, at -20°C for six months, or at -70°C for one year.

Target Details

Target: TNFSF14 (Tumor Necrosis Factor (Ligand) Superfamily, Member 14 (TNFSF14))

Alternative Name: LIGHT

Background: LIGHT is a member of the TNF family which includes TNF-α, TNF-β (lymphotoxin-alpha, LT-α), CD40 ligand, TRAIL (Apo2L), Fas ligand (FASL), and osteoprotegerin (OPG) ligand. LIGHT is a type II transmembranal protein that possesses 34 % identity with lymphotoxin beta (LT-β) and 31 % identity with FASL. LIGHT stimulates the proliferation of activated HVEM+ T-cells, NF-κB activation, and induces apoptosis in cells expressing both HVEM and LT-β receptors. B- and T- lymphocyte attenuators (BTLA) also bind to HVEM. LIGHT, as well as other members of the TNF/TNFR family, is released from the membrane by MMPs. It plays a key role for optimal IL-12 production by the dendritic cells (DCs) and the development of IFN-γ-producing CD4+ Th1 cells. Bone marrow-derived DCs from LIGHT (-/-) mice are severely impaired in IL-12p40 production after IFN-γ and LPS stimulation in vitro. LIGHT is expressed in lung inflammatory leucocytes after an allergen house dust mite challenge. It induces airway remodeling via the induction of TGF-β. The inhibition of LIGHT, using a fusion protein of Fc with the extracellular portion of the LT-β receptor (LTβR-Fc), prevents LIGHT-LTβR and LIGHT-HVEM interaction. In a mouse model of chronic asthma, this reduces lung fibrosis, smooth muscle and epithelial hyperplasia, and airway hyperresponsiveness through the suppression of lung TGF-β and IL-13 production. LIGHT has been shown to increase the anti-tumor immune response and its overexpression is associated with the survival in patients with colorectal cancer liver metastasis.

Molecular Weight: The 189 amino acid recombinant protein has a predicted molecular mass of approximately 20.5 kDa. The DTT-reduced and non-reduced protein migrate at approximately 30 and 28 kDa respectively by SDS-PAGE. The predicted N-terminal amino acid is His.

Pathways: Cancer Immune Checkpoints